Compare Agilent Technologies Inc (A) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Agilent Technologies Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Agilent Technologies Inc trades at $173.07 (market cap $48.79B), while State Street SPDR S&P Biotech ETF trades at $149.56 (market cap $10.55B). The key difference: Agilent Technologies Inc is far larger — about 4.6× State Street SPDR S&P Biotech ETF's market cap, and Agilent Technologies Inc pays a 0.59% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Agilent Technologies Inc for 38 Days and State Street SPDR S&P Biotech ETF for 41 Days on average.
| A | XBI | |
|---|---|---|
Market Cap | $48.79B | $10.55B |
Volume | 1,760,431 | 6,607,631 |
Sector | Health | Broad Market / Factor |
52-Week High | $177.76 | $169.55 |
52-Week Low | $110.24 | $108.04 |
Typical Hold Time | 38 Days | 41 Days |
Enterprise Value | $50.98B | — |
Dividend Yield | 0.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Agilent Technologies (A) trades at $173.9, down 2.17% today but near its 52-week high of $174.77 (Defense World, 2026-09-30). The stock exhibits a bullish technical trend with strong moving average signals. Fundamentally, the company maintains robust profitability with a 19.53% net income margin and has beaten earnings estimates in two of the last three quarters. Recent product launches, including the NovoStation and Gen5 AI module (Business Wire, September 2026), highlight innovation-driven growth.
The outlook remains positive with 80% analyst buy ratings and a consensus price target of $173.08, though the current price aligns closely with this target, suggesting limited near-term upside. Key risks include execution of the Ignite transformation program and macroeconomic sensitivity. Revenue growth from China and lab automation presents opportunities, but valuation multiples like a P/E of 34.14 warrant monitoring for sustainability.
XBI trades at $151.70, down 0.71% on the day, with technical indicators showing a neutral overall signal. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from recent M&A activity and positive clinical trial catalysts. Despite a 76% rally over the past year, analysts see continued potential with 8-14% total return expectations over the next 6-12 months.
The biotech sector shows renewed optimism with improved capital access and regulatory stabilization, though XBI carries higher volatility and expense ratios than broader healthcare ETFs. Key risks include sector-specific volatility and clinical trial outcomes, while catalysts include cancer vaccine developments and ongoing industry consolidation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Agilent Technologies Inc
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.
Read more on A →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
